$CBLI upper bollie & 10 day $2.02 Nasdaq CM W
Post# of 86
(Total Views: 475)
Posted On: 02/17/2017 4:32:21 PM
$CBLI upper bollie & 10 day $2.02
Nasdaq CM
Website
10-Q 11/14/16
Ultra low float
Shares Outstanding 10.99M
Float 2.84M
% Held by Insiders 3.83%
% Held by Institutions 3.00%
Shares Short 20.75k
Short Ratio 0.62
Short % of Float 0.47%
Shares Short (prior month) 3.17k
Last ten trades
Stock technical analysis
80% x 96% strong buy
News
and filings
Cleveland BioLabs, Inc., a biopharmaceutical company, focuses on developing pharmaceuticals designed to address diseases with unmet medical need. Its lead drug candidate includes Entolimod, a Toll-like receptor 5 (TLR5) agonist, which is used for the prevention of death from acute radiation syndrome, and is used as an oncology drug. The company is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. It has strategic partnerships with The Cleveland Clinic Foundation and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.
Nasdaq CM
Website
10-Q 11/14/16
Ultra low float
Shares Outstanding 10.99M
Float 2.84M
% Held by Insiders 3.83%
% Held by Institutions 3.00%
Shares Short 20.75k
Short Ratio 0.62
Short % of Float 0.47%
Shares Short (prior month) 3.17k
Last ten trades
Stock technical analysis
80% x 96% strong buy
News
and filings
Cleveland BioLabs, Inc., a biopharmaceutical company, focuses on developing pharmaceuticals designed to address diseases with unmet medical need. Its lead drug candidate includes Entolimod, a Toll-like receptor 5 (TLR5) agonist, which is used for the prevention of death from acute radiation syndrome, and is used as an oncology drug. The company is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. It has strategic partnerships with The Cleveland Clinic Foundation and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.
(0)
(0)Scroll down for more posts ▼